home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited From 02/21/23

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock OKYO Pharma  (NASDAQ: OKYO ) stock is falling on Tuesday as the company prepares for a presentation this week . OKYO Pharma is attending the 2nd Annual GPCRs-Targeted Drug Discovery Summi...
OKYO - OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to addre...

OKYO - OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its...

OKYO - Okyo stock rises 10% on FDA nod to start trial of dry eye disease therapy

The U.S. Food and Drug Administration (FDA) cleared Okyo Pharma's ( NASDAQ: OKYO ) investigational new drug (IND) to start a phase 2 trial of OK-101 for treating dry eye disease (DED). The London-based company said that the FDA previously agreed with its plans for designating...
OKYO - OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) --...

OKYO - OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, a...

OKYO - OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that i...
OKYO - OKYO Pharma Limited - PDMR dealing

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces tha...

OKYO - OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-...

OKYO - OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Monday, November 14 th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology bio-pharmaceutical company focusing on the discove...
Previous 10 Next 10